Marcin Filutowicz

Dr. Marcin Filutowicz, founded AmebaGone, Inc. in 2010 to commercialize a novel technology based upon the unique potential of free-living professional phagocytes (Dictyostelids or Dicty), found in soil and many other environments worldwide, to combat disease-causing microbes in affecting plants, water quality and human health.

Dr. Filutowicz and Katarzyna Borys from the Bacteriology Department of University of Wisconsin-Madison conceived the core technology. The inventors have assigned title for their work to AmebaGone and have executed a license to a collection of source material amassed by Dr. Kenneth Raper (also UW-Madison) with the Wisconsin Alumni Research Foundation (WARF). Filutowicz has developed biocontrol countermeasures to reduce infections caused by antibiotic-resistant bacteria since 1999. Dr. Filutowicz is a serial innovator, having co-founded ConjuGon Inc. in 2001 after inventing its technology. ConjuGon (now Atterx Biotherapeutics) is developing therapeutics to treat human bacterial infections. ConjuGon raised over $18M to advance its technology and is currently in Phase III clinical trials.